Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy

New England Journal of Medicine

Volumn 320, Issue 24, 1989, Pages 1592-1597

  Mendell, J R ^a   Moxley, R T ^b   Griggs, R C ^b   Brooke, M H ^c   Fenichel, G M ^d   Miller, J P ^c   King, W ^a   Signore, L ^a   Pandya, S ^b   Florence, J ^c   Schierbecker, J ^c   Robison, J ^d   Kaiser, K ^c   Mandel, S ^c   Arfken, C ^c   Gilder, B ^c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE;

ACNE; BEHAVIOR; CHILD; CUSHINGOID SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SIDE EFFECT; WEIGHT GAIN;

EID: 0024332294     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198906153202405     Document Type: Article

References (30)

1. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50: 509–17.
2. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kumit DM, Kunkel LM. Isolation of candidate cDN As for portions of the Duchenne muscular dystrophy gene. Nature 1986; 323: 646–50.
3. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–28.
4. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988; 318: 1363–8.
5. Arahata K, Ishiura S, Ishiguro T, et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1988; 333: 861–3.
6. Zubrzycka-Gaam EE, Bulman DE, Karpati G, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988; 333: 466–9.
7. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol 1987; 44: 812–7.
8. Mendell JR, Province MA, Moxley RT III, et al. Clinical investigation of Duchenne muscular dystrophy: a methodology for therapeutic trials based on natural history controls. Arch Neurol 1987; 44: 808–11.
9. Drachman DB, Toyka RV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974; 2: 1409–12.
10. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne muscular dystrophy: long-term benefit. Arch Neurol 1987; 44: 818–22.
11. Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy: report of a clinically matched three year double-blind study. IMJ 1974; 145: 32–3.
12. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy. II. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 1983; 6: 91–103.
13. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981; 4: 186–97.
14. Griggs RC, Forbes G, Moxley RT, Herr BE. The assessment of muscle mass in progressive neuromuscular disease. Neurology 1983; 33: 158–65.
15. SAS Institute Inc. SAS user's guide: statistics, version 6.03 edition. Cary, N.C.: SAS Institute, 1988:549–640.
16. Munsat TL, Piper D, Cancilla P, Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology 1972; 22: 335–47.
17. Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 1987; 30: 397–403.
18. Ringold GM. Steroid hormone regulation of gene expression. Annu Rev Pharmacol Toxicol 1985; 25: 529–66.
19. Ringold GM, Yamamoto KR, Bishop JM, Varmus HE. Glucocorticoid-stimulated accumulation of mouse mammary tumor virus RNA: increased rate of synthesis of viral RNA. Proc Natl Acad Sci USA 1977; 74: 2879–83.
20. Young HA, Shih TY, Scolnick EM, Parks WP. Steroid induction of mouse mammary tumor virus: effect upon synthesis and degradation of viral RNA. J Virol 1977; 21: 139–46.
21. Parrillo JE, Fauci AS. Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979; 19: 179–201.
22. Cesario TC, Slater L, Poo WJ, et al. The effect of hydrocortisone on the production of gamma-interferon and other lymphokines by human peripheral blood mononuclear cells. J Interferon Res 1986; 6: 337–47.
23. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193–208.
24. Seeman PW. Membrane stabilization by drugs: tranquilizers, steroids, and anesthetics. Int Rev Neurobiol 1966; 9: 145–221.
25. Weissmann G. Labilization and stabilization of lysosomes. Fed Proc 1964; 23: 1038–44.
26. Stracher A. Proteinase inhibitors and muscle degeneration. Muscle Nerve 1982; 5: 494.
27. Whitaker JN, Bertorini TE, Mendell JR. Immunocytochemical studies of cathepsin D in human skeletal muscle. Ann Neurol 1983; 13: 133–42.
28. Goldberg AL, Tischler M, DeMartino G, Griffin G. Hormonal regulation of protein degradation and synthesis in skeletal muscle. Fed Proc 1980; 39: 31–6.
29. Rennie MJ, Edwards RH, Millward DJ, Wolman SL, Halliday D, Matthews DE. Effects of Duchenne muscular dystrophy on muscle protein synthesis. Nature 1982; 296: 165–7.
30. Griggs RC, Rennie MJ. Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation? Ann Neurol 1983; 13: 125–32.